In ex vivo studies on diabetic patients, exenatide increased eNOS activation and NO production in ECs and reduced HG- or lipid-induced endothelial dysfunction in arterioles, both through GLP-1R and AMPK activation [215]. This evidence concerns the gene GLP1R and endothelial dysfunction.